secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2022-02-28T23:59:59+00:00
Accession:  0001193125-22-058273
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio Q4 net loss $25.1M, cash $765.4M; NUV-422 gets Fast Track
----------------------------------------------------------------------

- Net loss Q4 2021 was $25.1M ($0.12/share) vs $13.3M ($0.11) in Q4 2020.
- Full-year 2021 net loss $86.8M vs $41.7M in 2020; R&D spend $69.0M (up from $32.6M).
- Cash, equivalents, and marketable securities $765.4M as of Dec 31, 2021.
- FDA Fast Track for NUV-422 (high-grade gliomas); IND cleared for NUV-868 (solid tumors).
- Expects Phase 1 safety data for NUV-422 in 2022; multiple pipeline milestones planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312522058273/0001193125-22-058273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312522058273/d261084d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-058273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer